Navigation Links
OncoSec Medical Updates Analysis of Interim Data for Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
Date:3/25/2013

SAN DIEGO, March 25, 2013 /PRNewswire/ -- OncoSec Medical Inc. (OTCQB: ONCS) – a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors – announced positive, durable response results in an update on interim data from its Phase II metastatic melanoma trial. The data was presented at the HemOnc Today Melanoma and Cutaneous Malignancies Conference on March 22, in New York City.

(Logo: http://photos.prnewswire.com/prnh/20120905/LA68078LOGO)

In this analysis, all melanoma lesions that demonstrated at least a partial or complete response (PR or CR) to treatment with ImmunoPulse were followed, to determine durable response. Sixty-eight percent and forty-five percent of treated lesions demonstrated a durable response at three and six months, respectively.

Punit Dhillon , President and CEO said, "We are encouraged by this updated data from the interim analysis, especially in light of recent announcements related to durability of response for other intralesional therapies. This data not only shows that ImmunoPulse can effectively eliminate the targeted tumors but also that our treatment can have a lasting effect on those tumors."

Adil Daud , MD – the study's principal investigator at the University of California San Francisco – said, "This data demonstrates that the lesions we have selected for treatment are responding well to the therapy and that the ImmunoPulse can trigger a lasting immune response, against the treated lesion. It is now important for us to see if this local immune reaction can result in a more widespread response against untreated lesions."

These interim results reinforce previously announced Phase I data demonstrating that ImmunoPulse therapy is safe
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
2. OncoSec Medical Issues Letter to Shareholders
3. OncoSec Presents Preliminary Safety Data for Phase II Melanoma Study at Second European Post-Chicago Melanoma Meeting 2012
4. OncoSec Establishes Clinical Site for Its Phase II Merkel Cell Carcinoma Trial at University of California San Francisco (UCSF)
5. OncoSec OMS ElectroChemotherapy for Head and Neck Cancer Shows Enhanced Quality of Life in Two Randomized Phase III Studies
6. OncoSec Featured on KTVU-TV News and in San Francisco Chronicle
7. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
8. OncoSec Granted New Patent from China
9. OncoSec to Present at Upcoming Healthcare and Investor Conferences
10. OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
11. OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... Sept. 15, 2014 Research and Markets ... (CAS 103-90-2) Market Research Report 2014" report to ... Market Research Report 2014 presents comprehensive data on paracetamol ... , Asia , North ... includes paracetamol (acetaminophen) description, covers its application areas and ...
(Date:9/15/2014)... 15, 2014  MedExpress Urgent Care, a national leader in ... flu shots for ages four and up at each of ... get their flu shot early. According to ... of June, making late summer and early fall an ideal ... Vice President of Provider and Clinical Quality, Thomas Pangburn ...
(Date:9/15/2014)... PLYMOUTH MEETING, Pa. , Sept. 15, 2014 /PRNewswire/ ... today that it has met the stringent listing criteria ... has transferred to this U.S. stock exchange from the ... its current ticker symbol, "INO." NASDAQ ... Market, maintains the highest initial listing standards of any ...
Breaking Medicine Technology:Paracetamol (Acetaminophen) (CAS 103-90-2) Market Research Report 2014 2Paracetamol (Acetaminophen) (CAS 103-90-2) Market Research Report 2014 3MedExpress Quotes Late Summer, Early Fall As Best Time to Receive Flu Shot 2Inovio Pharmaceuticals (INO) Begins Trading on NASDAQ Global Select Market Exchange 2Inovio Pharmaceuticals (INO) Begins Trading on NASDAQ Global Select Market Exchange 3
... TOPAZ Technologies, a leading provider of biomedical research ... ML Weekes & Company, a professional services firm ... strategic partnership.  As a result of this partnership, ... solution through ML Weekes & Company,s RAMS grantsERA ...
... Texas, Nov. 16, 2010 Argon Medical Devices, Inc. ... licensing agreement with Rex Medical, LP ("Rex Medical") for ... dialysis catheter ™ on a global basis. UltraStream ™ ... patients receiving dialysis treatments. Argon will be ...
Cached Medicine Technology:TOPAZ Technologies and ML Weekes & Company Announce Partnership 2TOPAZ Technologies and ML Weekes & Company Announce Partnership 3Argon Medical Devices Announces Exclusive License and Distribution Agreement for 'UltraStream™' Chronic Hemodialysis Catheter 2
(Date:9/16/2014)... September 16, 2014 The Fertility Centers ... with Fairfax Egg Bank. The collaboration will give patients ... donor egg offering at the Fertility Centers of New ... and offers the nation’s largest selection of frozen donor ... several reasons:, , The Donor is ...
(Date:9/15/2014)... 16, 2014 The team of defective ... Danis & Lowe report that the company behind ... responsible for the injuries that a woman sustained after ... stress urinary incontinence (SUI). , Carey Danis & Lowe ... litigation and personal injury law. The St. Louis law ...
(Date:9/15/2014)... Phoenix, AZ (PRWEB) September 16, 2014 ... Law group in Phoenix Arizona announces one flat attorney ... in ensuring that clients retain the largest portion possible ... cover medical expenses, lost wages and damaged personal property. ... fee promise” to clients that simply states that no ...
(Date:9/15/2014)... (PRWEB) September 15, 2014 1Heart ... training for most staff of Regency Park Oak ... collaboration with their Executive Director Gladys Broxton. This ... and initiative of 1Heart Shirley Billedo and Regency ... Artiga, Marketing Director Jeanine Hernandez and Activities Coordinator ...
(Date:9/15/2014)... 2014 Aging skin inevitably wrinkles, thins and ... is loss of collagen production. By age 60, skin ... to this slow down. Collagen holds up skin structure. , ... be boosted. There are several ways to do this, but ... cells (non-embryonic). , "The cost is higher than other types ...
Breaking Medicine News(10 mins):Health News:FCNE Announces Partnership with Fairfax Egg Bank 2Health News:Carey Danis & Lowe Reports On $73 Million Boston Scientific Verdict 2Health News:Hastings And Hastings Announces One Flat Attorney Fee For Personal Injury Cases 2Health News:Hastings And Hastings Announces One Flat Attorney Fee For Personal Injury Cases 3Health News:1Heart Caregiver Services Training Director Randolph Neil Conducted In-Service Training at Regency Park Oak Knoll Pasadena 2Health News:1Heart Caregiver Services Training Director Randolph Neil Conducted In-Service Training at Regency Park Oak Knoll Pasadena 3Health News:1Heart Caregiver Services Training Director Randolph Neil Conducted In-Service Training at Regency Park Oak Knoll Pasadena 4Health News:A Superior Way to Make Skin Younger and Assure Continual Collagen Production, from Sublime Beauty® 2
... Fla. (Feb. 01, 2010) A research team from ... of transplanted hepatocyte (liver) cells in animal models severely ... whether and how transplanted hepatocytes were able to efficiently ... this study are published in the current double issue ...
... ... in providing accurate information on sexuality and toys for grown-ups, is proud to announce ... ... Vibrations ( www.goodvibes.com ), the legendary San Francisco-based company that takes pride in providing ...
... Partnership ... IT foundation to grow and maintain business, profitability , ... Austin, Texas (PRWEB) February 1, 2010 -- Pivot ... medium-sized businesses, today announced a partnership agreement with Brookside Technology Partners, Inc., an Austin-based ...
... , ATLANTA , Feb. 1 ... has launched a national campaign to promote physical activity and ... get up and dance. In partnership with Children,s Miracle Network, ... to submit 30-second home videos of their family,s best dance ...
... earlier detection and treatment, study suggests , MONDAY, Feb. ... rheumatoid arthritis long before a person notices symptoms, say ... and chemokines whose levels increase significantly as much as ... , People who receive an early and accurate diagnosis ...
... ... today that it has released a new version of its PASS Rx system. , ... Morrisville, NC (PRWEB) February 1, 2010 ... that it has released a new version of its PASS Rx system. PASS Rx ...
Cached Medicine News:Health News:Beyond liver transplants: Acutely damaged livers may be repaired via transplanted hepatocytes 2Health News:G Marks the Spot: Good Vibrations Proclaims February as National G-Spot Month -- Sex Toy Company Says "It Most Certainly Does Exist!" 2Health News:G Marks the Spot: Good Vibrations Proclaims February as National G-Spot Month -- Sex Toy Company Says "It Most Certainly Does Exist!" 3Health News:Pivot Networks and Brookside Technology Partners, Inc. Team to Broaden Managed IT Services Offering for Texas SMBs 2Health News:Pivot Networks and Brookside Technology Partners, Inc. Team to Broaden Managed IT Services Offering for Texas SMBs 3Health News:Dance Your Child's Way to a Healthy Body and Happy Heart 2Health News:Long Before Symptoms, Blood May Reveal Rheumatoid Arthritis 2Health News:Centice Corporation Enhances the PASS Rx System with its Version 3.0 Software Update 2
Optipress II Automated Blood Component Extractor for the standardized separation of whole blood into high purity individual components...
The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
eValuator fixed-curve diagnostic electrophysiology catheters offer an effective balance between clinical performance and cost....
... Two high performance technologies - Quantum™ ... shaft platform - unite in the ... a high dilatation force balloon with ... Laser bonded Maverick® shaft technology improves ...
Medicine Products: